Keith Dunleavy

Inovalon's 2015 prospectus says he earned a bachelor's degree in biology modified with engineering, with high honors, at Dartmouth, where his honors thesis was on computer simulation of artificial cerebellar units. It says he took his medical degree at Harvard Medical School, did his residency at Johns Hopkins Hospital in Baltimore, and practiced as a board-certified internist. Forbes gives the same degrees. His parents, where he grew up, and who paid for school are not established in anything opened here.

The prospectus says he has been chief executive since he organized the company's predecessor companies in 1998, and was president until May 2014. Wikipedia says the company started in Maryland as MedAssurant and took the Inovalon name in 2012. How the first money came in, and what he lived on during the early years, is not established. What separates this from a typical physician's career is that he was running a data business and not a practice for the next quarter century, though the sources opened here do not say what led him to start it.

By the 2015 offering the company had retained earnings of about $168 million. The prospectus says existing stockholders had put in about $92.8 million in total, which it says would be roughly 13 percent of all funding after the offering, with new investors supplying the other 87 percent. Who those earlier stockholders were is mostly not stated there, and I did not find a venture or angel round described. The same document says he chose not to take any bonus, incentive equity or raise while on the compensation committee in 2013.

Inovalon priced its Nasdaq offering at $27.00 a share in 2015, with expected net proceeds to the company of about $558.9 million. Class B shares carried ten votes to Class A's one, and the prospectus says Class B would hold about 98 percent of the voting power after the offering. It lists him as beneficially owning 44.8 percent of the shares before the offering. A footnote says some of those shares sit in entities owned by an irrevocable trust for his descendants, in which he says he has no pecuniary interest, so the number overstates what he personally held.

The merger proxy describes an all-cash deal at $41.00 a share, with an enterprise value of about $7.3 billion, by a consortium led by Nordic Capital. It says the buyers would not go ahead without a rollover, and that he agreed to roll $700 million of his holdings into the new owner. Entities tied to him held about 64 percent of the voting power at the time. The same document lists zero for him in golden-parachute pay. The proxy does not say how much cash he took out.

Forbes says he was CEO for 26 years and retired in 2025, still holds a stake of roughly 15 percent and sits on the board. It also says he founded Apandion, an investment firm funded entirely with his own money that backs founder-led technology companies and lists SpaceX and Shield AI among its holdings. The Dunleavy Foundation, which Forbes says he started with his wife in 2020, supports education, social entrepreneurship and veterans.

Forbes showed $4.6 billion on 21 October 2026, a real-time rank of 928, a self-made score of 9, age 57, and a home in Portsmouth, New Hampshire. It lists him as married with four children. The figure is an estimate, and how much of it is rolled-over equity versus cash is not established.

Two shareholder suits touched the company. The first, Xiang v. Inovalon Holdings, was a securities class action filed in 2016 in the Southern District of New York against the company, certain officers and directors, and the IPO underwriters. Inovalon's 8-K says it settled in 2019 for $17 million, with the company paying $1.7 million and insurers the rest, with no admission of liability. The second, City of Sarasota Firefighters' Pension Fund v. Dunleavy, was filed in Delaware in 2022 over the 2021 sale. The plaintiffs alleged, among other things, that the price was unfairly low, that the proxy had misstatements and omissions, and that he got a rollover benefit public holders did not. A settlement page reports that the Court of Chancery dismissed it in July 2023, the Delaware Supreme Court reversed in May 2024 on the ground that the proxy did not adequately disclose the advisors' conflicts, and the parties then agreed to a $44 million settlement, paid by the company and its insurers, with the defendants denying wrongdoing. Final approval was still pending as of this review. That summary comes from a secondary page. No court has found that he breached a duty. This is what I found in a few sources and it is not a clearance.